Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Key facts

Sponsor

Ohio State University

Principal Investigator

William D Arnold, MD

Ohio State University

Intervention

Ranolazine(drug)

Enrollment

35 enrolled

Eligibility

18-100 years · All sexes

Timeline

2014 – 2017

Study locations (1)

• The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

Collaborators

Gilead Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thomsen and Becker disease

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07008469
  Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT06411288
  Global Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.

See all trials for Thomsen and Becker disease →